OGN vs. ALNY, GMAB, TEVA, RPRX, BGNE, BMRN, VTRS, UTHR, RDY, and SRPT
Should you be buying Organon & Co. stock or one of its competitors? The main competitors of Organon & Co. include Alnylam Pharmaceuticals (ALNY), Genmab A/S (GMAB), Teva Pharmaceutical Industries (TEVA), Royalty Pharma (RPRX), BeiGene (BGNE), BioMarin Pharmaceutical (BMRN), Viatris (VTRS), United Therapeutics (UTHR), Dr. Reddy's Laboratories (RDY), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical preparations" industry.
Organon & Co. (NYSE:OGN) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, community ranking, media sentiment, valuation and risk.
Organon & Co. presently has a consensus price target of $22.60, suggesting a potential upside of 5.95%. Alnylam Pharmaceuticals has a consensus price target of $216.19, suggesting a potential upside of 45.65%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Organon & Co..
Alnylam Pharmaceuticals received 1074 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 76.17% of users gave Alnylam Pharmaceuticals an outperform vote while only 33.33% of users gave Organon & Co. an outperform vote.
In the previous week, Alnylam Pharmaceuticals had 4 more articles in the media than Organon & Co.. MarketBeat recorded 8 mentions for Alnylam Pharmaceuticals and 4 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.30 beat Alnylam Pharmaceuticals' score of 0.91 indicating that Organon & Co. is being referred to more favorably in the media.
Organon & Co. has a net margin of 16.50% compared to Alnylam Pharmaceuticals' net margin of -16.58%. Alnylam Pharmaceuticals' return on equity of 0.00% beat Organon & Co.'s return on equity.
Organon & Co. has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.
77.4% of Organon & Co. shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 1.4% of Organon & Co. shares are owned by company insiders. Comparatively, 1.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Organon & Co. has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, Alnylam Pharmaceuticals has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500.
Summary
Alnylam Pharmaceuticals beats Organon & Co. on 10 of the 18 factors compared between the two stocks.
Get Organon & Co. News Delivered to You Automatically
Sign up to receive the latest news and ratings for OGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organon & Co. Competitors List
Related Companies and Tools
